Background: The purpose of study was to evaluate radiologic or clinical features of breast cancer undergoing ultrasound (US)-guided 14G core needle biopsy (CNB) and analyze the differences between underestimated and accurately diagnosed groups. Materials and Methods: Of 1,898 cases of US-guided 14G CNB in our institute, 233 cases were proven to be cancer by surgical pathology. The pathologic results from CNB were invasive ductal carcinoma (IDC) (n=157), ductal carcinoma in situ (DCIS) (n=40), high-risk lesions in 22 cases, and benign in 14 cases. Among high-risk lesions, 7 cases of atypical ductal hyperplasia (ADH) were reported as cancer and 11 cases of DCIS were proven IDC in surgical pathology. Some 29 DCIS cases and 157 cases of IDC were correctly diagnosed with CNB. The clinical and imaging features between underestimated and accurately diagnosed breast cancers were compared. Results: Of 233 cancer cases, underestimation occurred in 18 lesions (7.7%). Among underestimated cancers, CNB proven ADH (n=2) and DCIS (n=11) were diagnosed as IDC and CNB proven ADH (n=5) were diagnosed at DCIS finally. Among the 186 accurately diagnosed group, the CNB results were IDC (n=157) and DCIS (n=29). Comparison of underestimated and accurately diagnosed groups for BI-RADS category, margin of mass on mammography and US and orientation of lesion on US revealed statistically significant differences. Conclusions: Underestimation of US-guided 14G CNB occurred in 7.7% of breast cancers. Between underestimated and correctly diagnosed groups, BI-RADS category, margin of the mass on mammography and margin and orientation of the lesions on US were different.
Introduction
Imaging-guided core needle biopsy (CNB) could be a reliable method for evaluating breast masses. Limited core sample specimen by CNB could miss atypical ductal hyperplasia (ADH) that include breast cancer portion within the breast lesion. Hence, surgical excisional biopsy or operation has been considered, even when ADHs are diagnosed at CNB because 23-65% of those lesions were upgraded to DCIS or IDC when revaluated after operation (Jang et al., 2008; Chae et al., 2009) . And DCIS underestimation occurs in CNB, which means a lesion yields DCIS at percutaneous breast needle biopsy with revealing invasive cancer at surgery (Suh et al., 2012) . DCIS underestimation is probably due to sampling error in a lesion that contains both DCIS and IDC.
Previous studies have suggested underestimation rates ranging from 6.25% to 65% for ADH and the underestimation rates of DCIS were from 16% to 66% by using various guiding methods including CNB or breast biopsy with vacuum assisted device (Crystal et al., 2005; Jang et al., 2008; Suh et al., 2012; Lee et al., 2013 ). There has been several studies about correlation with underestimation rate and clinical condition or radiologic findings such as Breast US or mammogram. Some study was evaluated to develop a scoring system for prediction of ADH underestimation at sonographically guided CNB (Ko et al., 2008) . Sonographic BI-RADS final assessment categories were not significantly associated with underestimation, but detailed sonographic features according to the BI-RADS lexicon were not analyzed. Youk et al. (2009) reported that US-guided CNB had a high underestimation of ADH with subsequent excision and there also was no clinical or radiological values including lesion characteristics and BI-RADS categories at mammography and sonography predicting upgrade to malignancy (Youk et al., 2009) . And there have been recent report about the comparisons between the underestimated breast lesions and accurately diagnosed breast lesion, especially ADH in US-guided 14G CNB with subsequent excision (Hsu et al., 2012) . So, when pathologic result revealed breast cancer with US-guided 14G CNB, our investigation was undertaken to compare the clinical and radiologic features between the underestimated breast cancer and accurately diagnosed breast cancer.
The purpose of our study was to determine the underestimation rate of US-guided 14G CNB and reveal the ultrasonography (US) and mammographic features of breast cancers, which was underestimated or accurately diagnosed by US-guided CNB and to compare of clinical and radiologic findings between underestimated and accurately diagnosed breast cancer.
Materials and Methods

Study population
Our institutional review board approved this retrospective observational study, and informed consent was not required from patients. Informed consent for all percutaneous biopsy procedures was obtained from all patients prior to biopsy. Between January 2007 and December 2009, percutaneous US-guided 14-gauge CNB was performed on 1898 consecutive breast lesions at our institution. Among the 1898 lesions, the 233 cases were surgical proved as breast cancer. Retrospectively, pathologic results on CNB were breast cancer in 197 cases, high-risk lesions in 22 cases, and benign in 14 cases (which were false negative results and excluded on this study). Among the CNB proven high-risk lesions, pathologic result revealed ADH (n=7) and other high-risk lesions (such as papillary lesion with atypia (n=10) or phyllodes tumors (n=4) or lobular neoplasm (n=1), which were potentially malignant lesion, but also debates for aspect of definition of underestimated cancer and so excluded on this study, n=15).
Among the CNB proven breast cancer, IDC (n=157) and DCIS (n=40) were reported. Surgically pathologic results of CNB proven DCIS cases were IDC (n=11) and DCIS, itself (n=29). So we included indication of cases about CNB proven ADH (n=7), CNB proven DCIS (n=40) or IDC (n=157) and categorized as underestimated breast cancer including 7 cases, which were ADH though CNB but final diagnosed at DCIS or IDC and 11 cases, which were DCIS by CNB and final diagnosed at IDC (total n=18) and accurately breast diagnosed cancer including 157 cases, proven IDC by CNB and 29 cases, proven DCIS with final diagnosed also DCIS (total n=186) ( Figure 1 ). US were available in all patients and mammograms of 12 of the 18 patients in underestimated breast cancer group and 149 of the 186 patients in accurately diagnosed breast cancer group were available.
Imaging and biopsy technique
Breast ultrasonography was performed with high resolution sonography unit with 7.5 or 12-MHz linear array transducers (ATL HDI 5000 or IU-22, Philips-Advanced Technology Laboratories, Bothell, WA, USA). The mammography was done with GE Senographe 2000D (GE Medical Systems, Milwaukee, WI, USA). US-guided CNBs were performed using a free-hand technique with a 14-gauge semi-automated core biopsy needle (Stericut, TSK, Japan).
US and biopsies were performed by one of 3 radiologists with fellowship training (n=1) or experienced radiologist in breast imaging and biopsy (n=2, each were 10 and 6 years of experiences). According to our standard protocol, five or six core samples were obtained, and the appearance of the formalin-fixed core samples were examined during the procedure to confirm that the targeted lesion was sampled adequately. Prior to biopsy, mammographic and sonographic findings were categorized according to BI-RADS, and the data were entered into a database using a computerized spreadsheet (Excel, Microsoft, Redmond, WA). The CNB results were divided into malignant, high-risk, and benign according to the pathologic report. We recommended definitive treatment for malignant lesions and advised excision for high-risk lesions.
Imaging review and analysis
After review of the surgical and CNB histologic findings, we categorized as accurately diagnosed breast cancer or underestimated breast cancer and the rate of underestimation was assessed. For each lesion, medical records, image findings of mammograms and sonograms also were reviewed, and clinical and radiologic variables were coded. The collected clinical variables were as follows: age, personal history of breast cancer, and associated symptoms. For collection of radiologic variables, each image was reviewed retrospectively by two radiologists (H. N. K and E. J. S) who were blinded to biopsy and operation pathology with consensus.
The prospectively assigned mammographic and sonographic BI-RADS categories were documented. We have subclassified or divided as category 4 into categories 4a, 4b, and 4c and recorded at data sheets. Mammographic visibility of the lesion such as focal asymmetry or asymmetry and lesion type (shape, margin and density of mass and calcification shape and distribution) were evaluated. The following sonographic features were determined according to the terminology of the American College of Radiology BI-RADS lexicon (American College of Radiology, 2003) such as shape, orientation, Asian Pacific Journal of Cancer Prevention, Vol 15, 2014 3181 DOI:http://dx.doi.org/10.7314/APJCP.2014.15.7.3179 US-guided 14G Core Needle Biopsy: Comparison Between Underestimated and Correctly Diagnosed Breast Cancers depth, margin, echogenicity, calcification and multiplicity.
Data analysis
The underestimated and the accurately diagnosed breast cancer were compared in terms of mammographic and US features, the size of lesion (as measured on the longest sonographic diameter), and tumor location and patient's age, symptom and history. Data were analyzed using the Chi-square test for nonparametric variables and the t-test for parametric variables. Statistical significance was indicated by a p value less than 0.05. All data was processed with commercially available software using the SYSTAT, version 5.2, statistical package (Systat, Evanston, IL).
Results
Of 233 cases of cancer, underestimation occurred in 18 lesions at percutaneous US-guided 14-gauge CNB (7.7%). Among the 18 underestimated breast cancers, the CNB results were: ADH (n=7) and DCIS (n=11) which were DCIS or IDC in final pathology (Figure 1) .
The analysis of clinical variables is summarized in Table 1 . The mean age of the patients was 46.1±14.5 years (range, 21-77 years), 50.6 years for patients with underestimated breast cancer and 49.1 years for those with accurately diagnosed breast cancer (p=0.53). One patient (6%) among the underestimated cancer group and 10 patients (5%) among the accurately diagnosed breast cancer group had a personal history of cancer of the contralateral breast. In terms of associated symptoms or past history, there was no statistically significant differences were found in between underestimated and accurately diagnosed group (p=0.57, p=0.31).
The analysis of mammographic findings is summarized in Table 2 . All lesions were classified as BI-RADS category. Relatively high BI-RADS categories was noted in accurately diagnosed breast cancer (p=0.01). Margin of mass on mammography revealed statistically significant difference between two groups (p=0.01). There was no statistically significant difference in asymmetry, shape and density of mass, presence of calcifications, shape and distribution of calcifications in between underestimation and accurately diagnosed group. Table 3 summarizes the sonographic features of all lesions according to BI-RADS descriptions. The mean diameter of the lesions measured at sonography was 31.9±9.2mm (range, 5-100mm), 37.5mm for 27 lesions). Our results showed no significant difference in the sizes, clinical variables such as patient's age, past history and associated symptom between underestimated and accurately diagnosed cases. So underestimation rate using US-guided CNB could be not related with clinical condition. Some reports show that almost underestimated breast cancers (93%) with vacuum suction biopsy were reported as calcifications on mammogram (Philpotts et al., 2000) . Our study suggest that the underestimation rate for calcifications were 9.4% (7/74) on mammogram and 12.5% (5/40) on US imaging, although we could not have targeted calcification only lesion on US imaging. But, our results showed no statistically significant difference about calcification on mammogram or US between underestimated and accurately diagnosed breast cancer groups (p=0.36, 0.93). The current study evaluated radiologic findings with DCIS or subtype of DCIS such as DCIS with microinvasion (positivity of sentinel lymph node biopsy), distinguishing in situ disease from microinvasive disease. There was no significant difference in the rates of microcalcifications or mass lesions on mammogram between the DCIS and DCIS with microinvasion patients. Further investigation with a larger patient database could be needed for better evaluating factors to characterize the potential microinvasion of DCIS among the patients with CNB proven DCIS (Ozkan-Gurdal et al., 2014) And our study showed that there were significantly differences for BIRADS category and margin of mass on mammogram in comparison between underestimated and accurately diagnosed breast cancer (p=0.01). For example, underestimation rate for microlobulated or obscured margin was in 28.5% (2/7) and 25% (1/4) on mammogram.
On US finding, margin of mass and orientation of mass on US showed significantly differences in comparison between underestimated and accurately diagnosed breast cancer (p=0.01). For example, underestimation rate for indistinct margin on US was 35.7% (5/14) on US. Interesting points were underestimation rates for non-parallel mass and parallel mass in 2.5% (3/118) and 17.4% (15/86) on US imaging. These radiologic findings affect results of BI-RADS category in two groups, so relatively lower BI-RADS category on underestimated breast cancer was described, compared with correctly diagnosed breast cancer. It means relatively pathologic finding of inherent ambiguity of ADH or DCIS, which is lack of stromal invasion area, could affect low suspicious finding, attributable with lower BIRAD category such as 1, 2, 3 and 4a on US and mammogram.
Our study had several limitations. First, this retrospective analysis was limited by the small sample size. Further investigation with a larger patient database is necessary to ascertain the factors, related to underestimation of US-guided CNB. Second, other borderline or high rick lesions such as papillary lesion with atypia or phyllodes tumor were excluded at underestimated breast cancer group without any explanation. These kinds of pathology entities should be considered further investigation. Finally there might have been selection bias, because surgically excised lesions with US-guided CNB at the same time on 
Discussion
When diagnosing of breast masses visible with sonography, US-guided CNB could be gold standard, replacing needle localization open surgical biopsy (Youk et al., 2008) . But, the CNB finding of ADH or DCIS is less reliable, due to histologic underestimation of breast malignancy.
Underestimation of ADH is an one of the important limitations of CNB. Pathologically, ADH is a borderline or high risk breast lesion, which fulfils some portion, but lacks meeting the strict criteria for DCIS. Comparing diagnostic criteria of DCIS, ADH is involved of a single duct or an aggregated diameter, less than 2mm and less extensive extension with same pathological findings labeling DCIS (Page et al., 1992; 1994) . The underestimation rates of ADH and DCIS have been reported to be 6.25-65% and 16.1-66.7% at variable gauges US-guided biopsy or stereotactic biopsy (Table 4 ). And underestimations range from 23.1 to 65% for ADH and from 29 to 66.7% for DCIS diagnosed using US-guided 14-gauge CNB have been stated previously (Crystal et al., 2005; Jang et al., 2008; Youk at al., 2008; Chae et al., 2009) .
Between January 2007 and December 2009, percutaneous US-guided 14-gauge CNB was performed on 1898 consecutive breast lesions. Among them, CNB proven ADH (n=13) and DICS (n=27) were diagnosed. Previous findings show similar results or including ranges in our study with ADH underestimation rate of 53.8% (7 of 13 lesions) and DCIS underestimation rate of 40.7% (11 of
